Medtronic, a leader in healthcare technology, has announced promising interim results from a study on sacral neuromodulation (SNM) therapy for treating overactive bladder (OAB). The research, part of the ongoing PEER 2 study, indicates that SNM therapy could be automated by using patients' physiological responses to stimulation. The analysis revealed a strong correlation between subjectively reported sensory thresholds and objectively measured sacral evoked response thresholds. Key findings showed that a high proportion of subjects exhibited measurable sacral evoked responses corresponding to their initial therapy trial program. This innovation could enhance the efficiency and consistency of OAB treatment, leveraging Medtronic's advanced sensing technology to improve patient outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.